Lung Disease Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Life Science Podcast

Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò — Episode 259

Pulmonary Hypertension Association on Improving Care Through Research and Advocacy

World Asthma Day 2026: New Anti-Inflammatory Drugs and More for Asthma Control

Risk-Based Monitoring in Clinical Trials: Improve Oversight Through Intelligent Review of Digital Endpoint Data

Respiratory Drug Development: Comprehensive Strategies to Improve Data Quality

Rethinking Idiopathic Pulmonary Fibrosis: Unmet Needs, Evolving Biology and the Future of Clinical Research

Boehringer’s Jascayd Scores Second FDA Approval in Lung Fibrosis

January 21, 2026

Life Science Spotlight

What Are the Key Considerations for Overcoming Challenges in IPF and Other Rare Respiratory Disease Clinical Trials?

December 11, 2025

Why RSV Protection for Infants in Canada Demands Awareness, Equity and Preparedness

December 3, 2025

Jascayd (Nerandomilast) Gains FDA Approval as First IPF Therapy in 10 Years

October 10, 2025

Top 5 Best-Selling Respiratory Disease Drugs to Watch in 2025

September 8, 2025

FDA Approves Brinsupri (Brensocatib), First Targeted Therapy for Non-Cystic Fibrosis Bronchiectasis

August 15, 2025

Overcoming IPF and Other Rare Respiratory Disease Clinical Trial Challenges

September 19, 2025

AZmed’s AZchest Receives Two FDA Clearances for AI-Powered Software Applications

From Symptoms to Solutions: Enhancing Interstitial Lung Disease (ILD) Trials with Next-Gen Assessments

Clinical Trial News

Nerandomilast Achieves Positive Phase III Results in Progressive Pulmonary Fibrosis

February 12, 2025

Next Page »